Spero Therapeutics, Inc (SPRO)

Etorro trading 970x250
Spero Therapeutics, Inc (SPRO) Logo

About Spero Therapeutics, Inc

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company is headquartered in Cambridge, Massachusetts. Address: 675 Massachusetts Avenue, Cambridge, MA, United States, 02139

Spero Therapeutics, Inc News and around…

Latest news about Spero Therapeutics, Inc (SPRO) common stock and company :

Spero Therapeutics to Present at Upcoming Investor Conferences
17 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Piper Sandler 33rd Annua

What Type Of Shareholders Make Up Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Registry?
12 Nov, 2021 Yahoo! Finance

Every investor in Spero Therapeutics, Inc. ( NASDAQ:SPRO ) should be aware of the most powerful shareholder groups...

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates
10 Nov, 2021 Yahoo! Finance

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 0.00% and 2.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update
10 Nov, 2021 Yahoo! Finance

Submitted NDA to U.S. FDA for tebipenem HBr for the treatment of complicated urinary tract infections, including pyelonephritis Entered into a non-dilutive revenue interest financing agreement with HealthCare Royalty Partners® for up to $125 million Conference call and live webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commerci

Sum Up The Parts: BIB Could Be Worth $131
03 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $130.92 per unit.

Spero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
03 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on Wednesday, November 10, 2021, at 4:30 p.m. ET to report its third quarter 2021 financial results and provide an

Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
28 Oct, 2021 Yahoo! Finance

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis
28 Oct, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA), seeking approval for tebipenem HBr tablets for the treatment of complicated uri

Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors
12 Oct, 2021 Yahoo! Finance

Ms. Tregoning brings more than two decades of experience in biotechnology and public policy to Spero’s BoardCAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Kathleen Tregoning to its Board of Directors. C

The Past Week's Notable Insider Buys Included Asana, Designer Brands, Evergy And More
09 Oct, 2021 FinancialContent

Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain. The week's most ...

3 Stocks Insiders Are Buying
05 Oct, 2021 FinancialContent

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. ...

Benzinga's Top Ratings Upgrades, Downgrades For October 1, 2021
01 Oct, 2021 FinancialContent

Upgrades Northland Capital Markets upgraded the previous rating for Five9 Inc (NASDAQ:FIVN) from Market Perform to ...

Spero Therapeutics Inks Revenue Interest Financing Agreement With HealthCare Royalty Partners
30 Sep, 2021 FinancialContent

Spero Therapeutics Inc(NASDAQ: SPRO) hasentered into a revenue interest financing agreementwith HealthCare Royalty ...

Add Up The Parts: XBI Could Be Worth $215
30 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $215.11 per unit.

Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners® for Up to $125 Million
30 Sep, 2021 FinancialContent

Investment expected to extend Spero Therapeutics’ cash runway into 2H 2023

Companies Like Spero Therapeutics (NASDAQ:SPRO) Are In A Position To Invest In Growth
28 Sep, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. Indeed, Spero Therapeutics...

Spero Therapeutics to Present Data at IDWeek 2021
16 Sep, 2021 FinancialContent
Spero Therapeutics to Present at Three Upcoming Investor Conferences
07 Sep, 2021 FinancialContent
4 Stocks Insiders Are Buying
02 Sep, 2021 FinancialContent

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. ...

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Aug, 2021 FinancialContent
Here's Why Momentum Investors Will Love Spero Therapeutics, Inc. (SPRO)
31 Aug, 2021 Yahoo! Finance

Does Spero Therapeutics, Inc. (SPRO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Notable Tuesday Option Activity: APPS, SPRO, PSFE
24 Aug, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Digital Turbine Inc (APPS), where a total of 19,078 contracts have traded so far, representing approximately 1.9 million underlying shares. That amounts to about 59.6% of APPS's average daily trading volume over the past month of 3.2 million shares..

58 Biggest Movers From Friday
23 Aug, 2021 FinancialContent

Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell ...

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why
11 Aug, 2021 Yahoo! Finance

Under the guidance of CEO Ankit Mahadevia, Spero Therapeutics, Inc. ( NASDAQ:SPRO ) has performed reasonably well...

Investing in Spero Therapeutics (NASDAQ:SPRO) three years ago would have delivered you a 28% gain
10 Aug, 2021 Yahoo! Finance

It might be of some concern to shareholders to see the Spero Therapeutics, Inc. ( NASDAQ:SPRO ) share price down 10% in...

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
05 Aug, 2021 Yahoo! Finance

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 18.18% and 101.88%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Recap: Spero Therapeutics Q2 Earnings
05 Aug, 2021 FinancialContent

Shares of Spero Therapeutics (NASDAQ:SPRO) moved lower in after-market trading after the company reported Q2 results. Quarterly ...

Spero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update
05 Aug, 2021 FinancialContent
Analysts Anticipate LABU Will Reach $97
05 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $96.81 per unit.

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Spero Therapeutics, Inc (SPRO) is a NASDAQ Common Stock listed in , ,

970x250